Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán

Translated title of the contribution: About the diagnosis, care and treatment of the intravascular B-cell lymphoma. Apropos of a case

István Takács, László Tordai, Nóra Eros, István Mórocz, Ferenc Bozsó, Zsuzsanna Károlyi, Gáspár Radványi, A. Matolcsy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The cutaneous angiotropic lymphoma has a poor prognosis. The diagnosis and the treatment are usually late. The mortality rate is over 80% and the majority of patients die within a year because of the tumorous infiltration of parenchymal organs. The authors report here the medical history and follow up of a still living patient suffering from cutaneous angiotropic lymphoma which has been diagnosed sixty months ago. During the successful treatment course systemic treatment with psoralen ultraviolet A-rays, chlorambucil and cyclophosphamid-doxorubicin-vincristin-methylprednisolon chemotherapy was applied, and for the management of the last relapse, rituximab-cyclophosphamid- doxorubicin-vincristin-methylprednisolon polychemotherapy was used. On the basis of findings in this case a treatment using an anti-CD20 monoclonal antibody could be a promising therapeutic alternative in the management of angiotropic B-cell lymphoma which otherwise considered to be a rare entity.

Original languageHungarian
Pages (from-to)843-848
Number of pages6
JournalOrvosi Hetilap
Volume146
Issue number18
Publication statusPublished - 2005

Fingerprint

B-Cell Lymphoma
Methylprednisolone
Doxorubicin
Lymphoma
Chlorambucil
Ficusin
Therapeutics
Skin
Ultraviolet Rays
Combination Drug Therapy
Monoclonal Antibodies
Recurrence
Drug Therapy
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Takács, I., Tordai, L., Eros, N., Mórocz, I., Bozsó, F., Károlyi, Z., ... Matolcsy, A. (2005). Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán. Orvosi Hetilap, 146(18), 843-848.

Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán. / Takács, István; Tordai, László; Eros, Nóra; Mórocz, István; Bozsó, Ferenc; Károlyi, Zsuzsanna; Radványi, Gáspár; Matolcsy, A.

In: Orvosi Hetilap, Vol. 146, No. 18, 2005, p. 843-848.

Research output: Contribution to journalArticle

Takács, I, Tordai, L, Eros, N, Mórocz, I, Bozsó, F, Károlyi, Z, Radványi, G & Matolcsy, A 2005, 'Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán', Orvosi Hetilap, vol. 146, no. 18, pp. 843-848.
Takács I, Tordai L, Eros N, Mórocz I, Bozsó F, Károlyi Z et al. Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán. Orvosi Hetilap. 2005;146(18):843-848.
Takács, István ; Tordai, László ; Eros, Nóra ; Mórocz, István ; Bozsó, Ferenc ; Károlyi, Zsuzsanna ; Radványi, Gáspár ; Matolcsy, A. / Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 18. pp. 843-848.
@article{f5c200419e814cb59469f21ca17974ae,
title = "Intravascularis B-sejtes lymphoma k{\'o}rism{\'e}z{\'e}s{\'e} rol, gondoz{\'a}s{\'a}r{\'o}l {\'e}s kezel{\'e}si lehetos{\'e}geirol egy eset{\"u}nk kapcs{\'a}n",
abstract = "The cutaneous angiotropic lymphoma has a poor prognosis. The diagnosis and the treatment are usually late. The mortality rate is over 80{\%} and the majority of patients die within a year because of the tumorous infiltration of parenchymal organs. The authors report here the medical history and follow up of a still living patient suffering from cutaneous angiotropic lymphoma which has been diagnosed sixty months ago. During the successful treatment course systemic treatment with psoralen ultraviolet A-rays, chlorambucil and cyclophosphamid-doxorubicin-vincristin-methylprednisolon chemotherapy was applied, and for the management of the last relapse, rituximab-cyclophosphamid- doxorubicin-vincristin-methylprednisolon polychemotherapy was used. On the basis of findings in this case a treatment using an anti-CD20 monoclonal antibody could be a promising therapeutic alternative in the management of angiotropic B-cell lymphoma which otherwise considered to be a rare entity.",
keywords = "CHOP, Cutaneous angiotropic lymphoma, Rituximab, Salvage treatment",
author = "Istv{\'a}n Tak{\'a}cs and L{\'a}szl{\'o} Tordai and N{\'o}ra Eros and Istv{\'a}n M{\'o}rocz and Ferenc Bozs{\'o} and Zsuzsanna K{\'a}rolyi and G{\'a}sp{\'a}r Radv{\'a}nyi and A. Matolcsy",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "843--848",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18",

}

TY - JOUR

T1 - Intravascularis B-sejtes lymphoma kórismézésé rol, gondozásáról és kezelési lehetoségeirol egy esetünk kapcsán

AU - Takács, István

AU - Tordai, László

AU - Eros, Nóra

AU - Mórocz, István

AU - Bozsó, Ferenc

AU - Károlyi, Zsuzsanna

AU - Radványi, Gáspár

AU - Matolcsy, A.

PY - 2005

Y1 - 2005

N2 - The cutaneous angiotropic lymphoma has a poor prognosis. The diagnosis and the treatment are usually late. The mortality rate is over 80% and the majority of patients die within a year because of the tumorous infiltration of parenchymal organs. The authors report here the medical history and follow up of a still living patient suffering from cutaneous angiotropic lymphoma which has been diagnosed sixty months ago. During the successful treatment course systemic treatment with psoralen ultraviolet A-rays, chlorambucil and cyclophosphamid-doxorubicin-vincristin-methylprednisolon chemotherapy was applied, and for the management of the last relapse, rituximab-cyclophosphamid- doxorubicin-vincristin-methylprednisolon polychemotherapy was used. On the basis of findings in this case a treatment using an anti-CD20 monoclonal antibody could be a promising therapeutic alternative in the management of angiotropic B-cell lymphoma which otherwise considered to be a rare entity.

AB - The cutaneous angiotropic lymphoma has a poor prognosis. The diagnosis and the treatment are usually late. The mortality rate is over 80% and the majority of patients die within a year because of the tumorous infiltration of parenchymal organs. The authors report here the medical history and follow up of a still living patient suffering from cutaneous angiotropic lymphoma which has been diagnosed sixty months ago. During the successful treatment course systemic treatment with psoralen ultraviolet A-rays, chlorambucil and cyclophosphamid-doxorubicin-vincristin-methylprednisolon chemotherapy was applied, and for the management of the last relapse, rituximab-cyclophosphamid- doxorubicin-vincristin-methylprednisolon polychemotherapy was used. On the basis of findings in this case a treatment using an anti-CD20 monoclonal antibody could be a promising therapeutic alternative in the management of angiotropic B-cell lymphoma which otherwise considered to be a rare entity.

KW - CHOP

KW - Cutaneous angiotropic lymphoma

KW - Rituximab

KW - Salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=22144487408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144487408&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 843

EP - 848

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18

ER -